Achillion: Bank of America Merrill Lynch Healthcare Conference (Achillion) - May 16, 2013 - Anticipated rapid virological response data from P2a (sovaprevir+ACH-3102+rbv) 007 trial for hep C infection in Q3 2013; Anticipated sustained virological response data from P2a (sovaprevir+ACH-3102+rbv) 007 trial for hep C infection in Q4 2013; Anticipated sustained virological response data from P2a (sovaprevir+ACH-3102) trial for genotype 1 hep C infection in fall 2013
Anticipated P2a data • Hepatitis C Virus
|